A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
Public ClinicalTrials.gov record NCT05582993. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With Vonicog Alfa (rVWF) in Children Diagnosed With Severe Von Willebrand Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aim of the study is to evaluate the effectiveness of prophylaxis with vonicog alfa (recombinant von Willebrand factor \[rVWF\]) in children. This study will enroll those participants who have been previously treated with VWF product or with a plasma-derived VWF (pdVWF) product. In this study, participants will be treated with vonicog alfa (rVWF) for 12 months. During the study, participants will visit the study clinic 5 times after treatment initiation.
Study identification
- NCT ID
- NCT05582993
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Up to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 5, 2024
- Primary completion
- Apr 10, 2030
- Completion
- Apr 10, 2030
- Last update posted
- May 26, 2026
2024 – 2030
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35223 | Recruiting |
| Bleeding and Clotting Disorders Institute | Peoria | Illinois | 61614 | Recruiting |
| Riley Hospital for Children Indiana University Health | Indianapolis | Indiana | 46202 | Recruiting |
| University of Iowa Hospitals & Clinics PARENT | Iowa City | Iowa | 52242 | Recruiting |
| Childrens Hospital of Michigan | Detroit | Michigan | 48201 | Recruiting |
| Michigan State University Center for Bleeding Disorders & Clotting Disorders | East Lansing | Michigan | 48824 | Recruiting |
| Children's Health Care d/b/a Children's Minnesota | Minneapolis | Minnesota | 55404 | Recruiting |
| Cure 4 the Kids | Las Vegas | Nevada | 89135 | Recruiting |
| Rutgers - Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08901 | Recruiting |
| New York - Presbyterian/Weill Cornell Medical Center | New York | New York | 10021 | Recruiting |
| Medical University of South Carolina (MUSC) | Charleston | South Carolina | 29425 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05582993, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05582993 live on ClinicalTrials.gov.